NO3014707T3 - - Google Patents

Info

Publication number
NO3014707T3
NO3014707T3 NO15745380A NO15745380A NO3014707T3 NO 3014707 T3 NO3014707 T3 NO 3014707T3 NO 15745380 A NO15745380 A NO 15745380A NO 15745380 A NO15745380 A NO 15745380A NO 3014707 T3 NO3014707 T3 NO 3014707T3
Authority
NO
Norway
Application number
NO15745380A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3014707T3 publication Critical patent/NO3014707T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO15745380A 2013-12-26 2015-06-23 NO3014707T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26

Publications (1)

Publication Number Publication Date
NO3014707T3 true NO3014707T3 (enExample) 2018-01-06

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15745380A NO3014707T3 (enExample) 2013-12-26 2015-06-23

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3087070B1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA029757B1 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000808A2 (pt) * 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CN106467541B (zh) 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
EP3558991A2 (en) * 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11623923B2 (en) * 2017-11-24 2023-04-11 Medshine Discovery, Inc. Uracil compound as c-MET/AXL inhibitor
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
ES2985569T3 (es) * 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
JP7542613B2 (ja) * 2019-09-06 2024-08-30 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Axlとc-Metキナーゼ阻害活性を有する化合物およびその製造と使用
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022019517A2 (pt) 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
JP7802077B2 (ja) * 2021-07-13 2026-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l,2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
AU2024319770A1 (en) 2023-08-07 2026-02-19 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
US20100004238A1 (en) * 2006-12-12 2010-01-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
EA030141B1 (ru) * 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
MA34969B1 (fr) * 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
US9914731B2 (en) 2018-03-13
AU2014370186A1 (en) 2016-07-14
US20160318929A1 (en) 2016-11-03
PL3087070T3 (pl) 2018-03-30
SG11201605207PA (en) 2016-07-28
WO2015100117A1 (en) 2015-07-02
CN106029661B (zh) 2017-11-03
ES2654931T3 (es) 2018-02-15
EP3087070B1 (en) 2017-11-08
CA2934667A1 (en) 2015-07-02
CL2016001604A1 (es) 2017-05-26
IL246311A0 (en) 2016-08-02
SI3087070T1 (en) 2018-01-31
KR20160110390A (ko) 2016-09-21
PH12016501232A1 (en) 2016-08-15
BR112016015057A2 (pt) 2017-08-08
EP3309160A1 (en) 2018-04-18
DK3087070T3 (en) 2017-12-04
MX2016008445A (es) 2016-10-28
HUE037579T2 (hu) 2018-09-28
EA201890061A2 (ru) 2018-05-31
EP3087070A1 (en) 2016-11-02
JP2017500362A (ja) 2017-01-05
EA029757B1 (ru) 2018-05-31
EA201691164A1 (ru) 2016-12-30
AU2014370186A2 (en) 2016-07-21
EA201890061A3 (ru) 2018-09-28
CN106029661A (zh) 2016-10-12
PT3087070T (pt) 2018-01-30
US20180148447A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112016004195A2 (enExample)
BR112015007533A2 (enExample)
BR112014018502A2 (enExample)
BR112016003412A2 (enExample)
BR112014019326A2 (enExample)
BR112014018516A2 (enExample)
BR112014018480A2 (enExample)
BR112014017855A2 (enExample)
BR112014020341A2 (enExample)
BR112016005446A2 (enExample)
BR112015026369A2 (enExample)
BR112014017765A2 (enExample)
NO3014707T3 (enExample)
BR112014021878A2 (enExample)
BR112016012903A2 (enExample)
BR112014018468A2 (enExample)
BR112014019204A2 (enExample)
BR112014017901A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112016004357A2 (enExample)
BR112014017794A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112015015312A2 (enExample)